Comparative Pharmacology
Head-to-head clinical analysis: IMITREX versus OLEPTRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMITREX versus OLEPTRO.
IMITREX vs OLEPTRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
50 mg to 100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. Alternatively, 6 mg subcutaneously once, may repeat after 1 hour, max 12 mg/day. Intranasal: 5 mg to 20 mg in one nostril at onset; may repeat after 2 hours, max 40 mg/day.
IV: 1 g every 12 hours; oral: 750 mg every 12 hours
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range 2–3 hours). This short half-life supports its use for acute migraine attacks but may require repeat dosing for prolonged symptoms.
Terminal elimination half-life: 12-15 hours (mean 13.5 h) in steady state; clinical context: allows twice-daily dosing, prolonged in renal impairment (up to 27 h in severe disease)
Primarily renal excretion of unchanged drug and metabolites (approximately 80% of total clearance), with about 20% eliminated in feces via biliary excretion. About 40% of the dose is excreted unchanged in urine.
Renal: 70% as unchanged drug; Hepatic metabolism: 30% (minor CYP2D6), excreted in feces via bile
Category C
Category C
Triptan
Triptan